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Background: The resumption of menses is an important indicator of recovery in anorexia nervosa (AN). Patients
with early-onset AN are at particularly great risk of suffering from the long-term physical and psychological
consequences of persistent gonadal dysfunction. However, the clinical variables that predict the recovery of
menstrual function during weight gain in AN remain poorly understood. The aim of this study was to investigate the
impact of several clinical parameters on the resumption of menses in first-onset adolescent AN in a large,
well-characterized, homogenous sample that was followed-up for 12 months.
Methods: A total of 172 female adolescent patients with first-onset AN according to DSM-IV criteria were recruited
for inclusion in a randomized, multi-center, German clinical trial. Menstrual status and clinical variables (i.e., premorbid
body mass index (BMI), age at onset, duration of illness, duration of hospital treatment, achievement of target weight
at discharge, and BMI) were assessed at the time of admission to or discharge from hospital treatment and at a
12-month follow-up. Based on German reference data, we calculated the percentage of expected body weight
(%EBW), BMI percentile, and BMI standard deviation score (BMI-SDS) for all time points to investigate the relationship
between different weight measurements and resumption of menses.
Results: Forty-seven percent of the patients spontaneously began menstruating during the follow-up period. %EBW at
the 12-month follow-up was strongly correlated with the resumption of menses. The absence of menarche before
admission, a higher premorbid BMI, discharge below target weight, and a longer duration of hospital treatment
were the most relevant prognostic factors for continued amenorrhea.
Conclusions: The recovery of menstrual function in adolescent patients with AN should be a major treatment
goal to prevent severe long-term physical and psychological sequelae. Patients with premenarchal onset of AN are
at particular risk for protracted amenorrhea despite weight rehabilitation. Reaching and maintaining a target
weight between the 15th and 20th BMI percentile is favorable for the resumption of menses within 12 months.
Whether patients with a higher premorbid BMI may benefit from a higher target weight needs to be investigated
in further studies.
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Anorexia nervosa (AN) is a psychiatric disorder that typ-
ically first occurs in adolescence and is the third-most
common chronic illness in this age group, after asthma
and obesity [1]. AN often has a protracted course and is
associated with an array of medical and psychiatric
comorbidities [2,3].
Although the DSM-5 has abandoned amenorrhea as a
diagnostic criterion for AN, there is general agreement
that the resumption of menses is an important indicator
of recovery from AN [4-6]. Thus, pediatric and psychiatric
guidelines highlight the resumption of menses as an im-
portant goal in their recommendations for the treatment
of AN [7-9].
Prolonged amenorrhea is a factor that likely contributes
to poor physical outcome in AN. Patients with adolescent-
onset AN are at particular risk of suffering from long-
term physical and neuropsychiatric consequences of
continuous gonadal dysfunction. Bone mineral accrual
occurs mainly during adolescence [10]. Persistent amen-
orrhea at this age may lead to reduced peak bone mass
and result in an increased risk for bone fractures later
in life [11]. Studies have revealed that the normalization
of body weight alone does not improve bone density;
rather, the optimization of body weight and the normal-
ization of gonadal status are necessary [12-14]. Moreover,
in adolescent AN, starvation-induced hormonal deficien-
cies may lead to impairments in the maturation of certain
brain regions that result in deficits in neuropsychological
functioning [15-17]. Accordingly, it was shown that abnor-
mal menstrual function in adolescent patients with AN is
associated with deficits in verbal learning and memory,
visual reproduction, working memory, and mathemat-
ical skills [15].
Weight rehabilitation is a prerequisite for reestablish-
ing endocrine function [11,18,19]. During weight gain,
fat mass increases resulting in the normalization of go-
nadal hormones and leptin levels. Leptin is a neuropeptide
that is involved in various neuroendocrine and behavioral
alterations associated with starvation [11,20]. However,
some individuals remain amenorrheic for years despite
stable weight recovery [21,22]. Currently, the clinical pa-
rameters that predict recovery of hypothalamic-pituitary-
ovarian function during weight gain in AN remain poorly
understood.
The ability to predict the magnitude of weight gain
required for regular ovulatory cycles and a better un-
derstanding of the factors underlying the time lag between
weight recovery and menstrual resumption would aid
clinicians in determining their patients’ target weights.
BMI at admission [23], BMI at discharge [24], and BMI
before the onset of AN (“premorbid BMI”) [25,26] have
been found to be important factors associated with
the recovery of menstrual function and thus may aidin predicting the probability of resumption of menses
in patients with AN.
However, there is no agreement on the definition of
target weight. The American Psychiatric Association states
that “a healthy goal weight for female patients is the
weight at which normal menstruation and ovulation are
restored” and that a healthy weight is “approximately
the same weight at which full physical and psychological
vigor were present” [7]. These definitions are based on
the finding of two studies [27,28] that normal menstrual
cycles are more likely to occur if the difference between
the target weight and the body weight at which men-
struation ceased is small.
Further studies have shown that in adult women with
AN, a BMI higher than 18 kg/m2 is a relevant factor
associated with the normalization of reproductive func-
tion [24-26,29].
In adolescents, the determination of target weight is
even more complex, as both height and weight are
expected to increase during this developmental period
[30] and absolute BMI changes with age [31]. Golden et al.
[30] recommended the use of BMI percentile ranges of
the 14-39th percentile to assign a treatment goal weight.
Other researchers calculated the percent of expected
body weight (%EBW) on the basis of BMI percentiles
according to the recommendation of Le Grange et al.
[32] and found that 2/3 of the patients resume menses
at 95% of their expected body weight (%EBW) [33].
Swenne et al. [28] suggested the use of BMI standard
deviation scores (BMI-SDS) to determine weight require-
ments for the resumption of menses in adolescents. Nei-
ther the American Psychiatric Association or American
pediatric guidelines [9] nor the NICE guidelines provide
a clear recommendation for the determination of target
weight. The American Psychiatric Association notes that
“the closer a patient is to his or her healthy body weight
before discharge, the less the risk he or she has of relaps-
ing and being readmitted” and recommends the use of
population reference data (e.g., growth charts of the
Centers for Disease Control and Prevention) to set indi-
vidually appropriate and realistic goals for weight in
adolescent patients [7,34]. In the German guidelines [8],
the target weight in adolescents is defined as the 25th,
but at least the 10th, BMI percentile, based on German
reference data [35]. Thus, in our treatment program, we
determined a discharge weight that was close to the tar-
get weight as defined above according to the German
guidelines, and patients had to maintain this weight
during outpatient treatment.
The aim of this study was to investigate the impact of
several clinical parameters on the resumption of menses
in a large, well-characterized, homogenous sample of
first-onset adolescent AN patients who were followed up
for 12 months.
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Patients
The patients in this study were recruited within a ran-
domized, multi-center clinical trial comparing inpatient
and day-patient treatment for adolescent AN (the results
of that investigation will be published elsewhere; [36]).
The study was performed at four university hospitals
(RWTH Aachen, University of Würzburg, Charité
Universitätsmedizin Berlin, University of Freiburg and
Medical Faculty of Mannheim of Heidelberg University)
and one major general hospital (Köln) in various regions
of Germany between February 2007 and April 2010, and
the follow-up period lasted until April 2011. The inclusion
criteria were as follows: female gender, age between 11
and 18 years, a diagnosis of AN based on DSM-IV criteria,
and first admission for AN. The weight threshold for
inclusion in the study was a BMI below the 10th per-
centile (based on a large German reference set [35]).
This threshold is considered to be consistent with the
international convention for the definition of AN
[31,37] and corresponds to the German guidelines for
eating disorders [8]. Patients were excluded from the
study if they had an organic brain disease, a psychotic
disorder, bipolar disorder, substance dependence or
abuse, serious self-injurious behavior, or an IQ below
85. All patients who were admitted for inpatient treat-
ment were screened for the study. The trial aimed to
include a series of consecutively presenting adolescent pa-
tients with AN that was as complete as possible.
The study was approved by the local research ethics com-
mittees of the four participating universities (RWTH Aachen,
University of Wuerzburg, Charité Universitaetsmedizin
Berlin, University of Freiburg, Medical Faculty of Mannheim
of Heidelberg University) and the ethics committee of the
regional Medical Association (Nordrhein; Koeln-Holweide).
After a complete description of the study was provided to
the subjects, written informed consent was obtained from
all participants and their parents or legal guardians.
All patients fulfilling the study criteria were initially
admitted to a three-week inpatient care program. Subse-
quently, the patients were randomized into two treatment
settings (continued inpatient or day-patient treatment).
An identical multimodal multidisciplinary treatment pro-
gram was used in both treatment arms that included
weight restoration, individual and group nutritional coun-
seling, cognitive-behavioral individual and group therapy,
individual family sessions, and a group psychoeducation
program for parents (for further details, see [38]). Accord-
ing to the German guidelines for eating disorders [8] and
consistent with other clinical practices [30], patients were
regularly discharged when they had maintained their
predetermined target weight corresponding to the 15-20th
age-adjusted BMI percentile for two weeks. Discharge
against medical advice was defined as premature drop-outfrom treatment without achievement of the predeter-
mined target weight. After discharge, patients were pro-
vided access to the same outpatient treatment program,
including cognitive-behavioral individual and group ses-
sions, joint family sessions, and nutritional therapy (for
further details, see [38]). A hospital readmission was ini-
tiated if the patients fell below a pre-determined weight
(usually corresponding to the 10th BMI percentile). The
12-month follow-up (12 months after admission) was
defined as the primary outcome assessment time point.
Menstrual status
Menstrual status was assessed at admission, discharge,
and 12 months after admission. Brief assessments of men-
strual status were also performed at regular outpatient
visits. For amenorrheic patients, we assessed whether the
patients were premenarchal (no menarche at age <16 years),
had primary amenorrhea (no menarche by the age
of ≥16 years [39]), or had secondary amenorrhea.
We compared two different patient groups: those who
resumed menstruation spontaneously within the first
12 months after admission to the hospital treatment pro-
gram and those who did not. The “menstruating group”
consisted of patients who were menstruating at any time
prior to follow-up and were not taking oral contraceptives
(OCs) or who reported spontaneous resumption of men-
ses before the use of OCs. In the “amenorrheic group”,
we included patients who were still amenorrheic at the
12-month follow-up. Patients were excluded if men-
strual status information was missing at the 12-month
follow-up or before the initiation of OCs.
Clinical variables
Clinical variables were assessed at admission, dis-
charge, and 12 months after admission. At each time
point, the evaluations consisted of measurements of
weight (measured with the patients in their under-
wear) and height, from which BMIs were calculated.
Age- and sex-adjusted BMI standard deviation scores
(BMI-SDS), BMI percentiles, and percentages of ex-
pected body weight (%EBW, where the expected
body weight (EBW) is the median age-adjusted BMI
(50th BMI-percentile), and, thus, the %EBW is the
observed BMI/EBW × 100 [32]) were calculated
based on a large German population-based normative
data set [35]. This reference population for children
and adolescents was compiled from measurements
from 17 studies conducted in different regions in
Germany between 1985 and 1999 (17147 males,
17274 females, 0 to 18 years of age). At admission,
age, age at AN onset (defined as the earliest of the
following times: (1) the approximate time at which
weight loss first occurred; (2) at which, despite age-
appropriate growth spurts, no further weight gain
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first occurred), duration of illness (the time between
the onset of AN and admission), and premorbid BMI
(BMI before illness onset) were assessed. At discharge,
the duration of hospital treatment and discharge modal-
ity (regular discharge at target weight or discharge
against medical advice based on persisting AN symp-
toms and failure to meet the target weight) were re-
corded for each patient.Statistical analysis
Patients who were excluded from the analysis of men-
strual status and those who were included were compared
with respect to all clinical variables available until dis-
charge (see above) using ANOVA. To compare the
menstruating and amenorrheic groups, we performed
logistic regression analyses. The independent clinical
variables available until discharge were used as predictors
(quantitative variables: age at admission, age at AN onset,
age at menarche, premorbid BMI and BMI, BMI-SDS,
BMI percentile and %EBW (at admission and discharge),
duration of hospital treatment; binary variables: premenar-
chal or postmenarchal state at admission, regular dis-
charge or discharge against medical advice). To analyze
the relationship between menstrual status and cuurent
weight, we also used %EBW at the 12-month follow-up as
an independent variable. Descriptive data (evaluated by
univariate analyses) are provided separately for the two
groups as the means and standard deviations (or numbers
and percent), together with the p-values from univariate
logistic regression. Multivariate model selection using a
stepwise procedure based on the Akaike information
criterion (AIC) was performed. The primary statistical
analyses were performed using %EBW as an appropriate
measure for body weight in adolescents; in addition, we
also report absolute BMI (enabling a better comparison
with studies in adult AN patients), BMI percentiles, and
BMI-SDS.
To evaluate the predictive accuracy of the logistic models,
we used the area under the receiver operating characteristic
curve (AUC of the ROC; sensitivity vs. specificity). The
AUC is the probability that the risk score of a randomly
picked non-menstruating patient is less than the risk
score of a menstruating patient and measures the dis-
crimination ability of the variables included in the logis-
tic model. We compared the AUCs of different ROC
curves (from models with and without %EBW at follow-
up) using DeLong’s test [40].
Treatment setting (inpatient or day-patient) was not
considered in the present analysis of menstruation be-
cause the durations of treatment and therapy outcomes
with respect to BMI at discharge and at the 12-month
follow-up were similar in the two treatment arms(95% confidence interval for difference in BMI at 12-
month follow-up: -0.11 to 1.02; [36]).
Results
Data at baseline and at the 12-month follow-up
A total of 172 patients were included in the clinical trial.
At admission, all patients were amenorrheic. Most of the
patients reported secondary amenorrhea, while 36 patients
(20.9%) were premenarchal (31 patients) or had primary
amenorrhea (5 patients).
At the 12-month follow-up, information about men-
struation was missing in 13 patients, and 7 patients were
taking OCs and had missing information regarding men-
strual status prior to OC use. Thus, a total of 20 patients
could not be included in our analyses. However, the
excluded patients were similar to the included patients
with respect to all investigated variables assessed until
discharge (all p-values >0.15).
Therefore, the final sample used in the analysis in-
cluded 152 patients. Seventy-two of these patients (47%)
had spontaneously resumed menses during the follow-
up period. However, 80 patients (53%) were still amenor-
rheic. Among these patients, 25 were premenarchal and
5 had primary amenorrhea. The clinical data at admission,
discharge, and the 12-month follow-up are provided in
Table 1.
There was a strong association between patients’ %EBW
at the 12-month follow-up and the resumption of menses
(p = 0.0003, univariate logistic regression). The %EBW at
follow-up was the variable that best discriminated between
groups, as shown by an AUC of 0.69. Considering the
absolute BMI data, this result means that a reduction in
BMI of 1 kg/m2 approximately doubled the odds of per-
sistent amenorrhea (OR = 1.94).
Prognostic variables for the resumption of menstruation
Among the variables that were available until discharge
and could thus be used as prognostic factors, the most
important variable for the resumption of menstruation
was “no menarche at admission” (p = 0.00003, univariate
logistic regression; AUC of 0.67). Patients who had never
menstruated before had a 14-fold increase in the odds of
remaining amenorrheic compared with the patients with
secondary amenorrhea (OR = 13.8). A multiple logistic
regression (adjusted for age; p = 0.17) revealed that no
menarche (p = 0.0003), premorbid %EBW (p = 0.04), dur-
ation of hospital treatment (p = 0.03), and regular discharge
at the target weight (p = 0.01) were the relevant prognostic
factors prior to discharge. The joint predictive value of
these clinical variables was high (AUC of 0.76). Although
%EBW at the 12-month follow-up was strongly correlated
with the resumption of menses, it did not add much to
the discrimination power of the multivariate logistic re-
gression (AUC of 0.83, p = 0.2 for the difference between
Table 1 Clinical data at admission, discharge and 12 months after admission for patients with and without
spontaneous resumption of menses within the first 12 months after admission
Menstruating Amenorrheic p-valuea
n = 72 n = 80
Mean (SD) or n (%) Mean (SD) or n (%)
premorbid BMI (kg/m2) 20.2 (2.8) 19.9 (2.8) 0.61
premorbid BMI-percentile 49.0 (29.3) 49.4 (28.2) 0.94
premorbid BMI-SDS 0.0 (1.0) 0.0 (0.9) 0.96
premorbid %EBW 101.6 (14.0) 101.7 (13.8) 0.98
age at menarche (years) 12.5 (1.2) 12.3 (1.0) 0.49
age at onset of AN (years) 14.5 (1.4) 14.1 (1.4) 0.09
duration of illness (months) 11.5 (9.4) 9.9 (7.2) 0.23
no menarche at admission 3 (4.2%) 30 (37.5%) <0.0001
- premenarchal 3 (4.2%) 25 (31.25%)
- primary amenorrhea 0 5 (6.25%)
age at admission (years) 15.4 (1.3) 14.9 (1.6) 0.03
BMI at admission (kg/m2) 15.3 (1.2) 14.8 (1.4) 0.02
BMI-percentile at admission 2.0 (3.1) 2.2 (5.1) 0.84
BMI-SDS at admission ′-2.0 (3.1) −2.2 (5.1) 0.84
%EBW at admission 75.4 (6.1) 74.1 (7.1) 0.24
duration of treatment (weeks) 14.7 (5.4) 16.8 (7.2) 0.05
regular discharge* 56 (77.8%) 49 (61.2%) 0.03
BMI at discharge (kg/m2) 18.2 (0.9) 17.8 (1.1) 0.01
BMI-percentile at discharge 19.4 (8.0) 17.8 (1.1) 0.01
BMI-SDS at discharge ′-0.9 (0.5) ′-1.0 (0.4) 0.28
%EBW at discharge 89.2 (4.2) 88.4 (4.2) 0.21
BMI at 12-month follow-up (kg/m2) 18.8 (1.7) 17.5 (1.4) <0.0001
BMI-percentile at 12-month follow-up 24.0 (21.3) 13.3 (14.1) 0.0013
BMI-SDS at 12-month follow-up ′-0.8 (0.7) ′-1.4 (0.7) <0.0001
%EBW at 12-month follow-up 91.1 (8.7) 85.7 (7.0) 0.0003
BMI = body mass index, %EBW = % expected body weight.
*regular discharge = when target weight (between the 15 and 20th BMI percentiles) was maintained for two weeks.
ap-value from univariate logistic regression.
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regression model, only no menarche at admission
(p = 0.0005), premorbid %EBW (p = 0.007), and %EBW
at follow-up (p = 0.0009) were significant, and the dis-
charge variables (i.e., duration of treatment (p = 0.08)
and regular discharge (p = 0.16)) were no longer signifi-
cant. The parameter estimate for premorbid %EBW
was inversely correlated with the resumption of menses
compared with %EBW at the 12-month follow-up, i.e., a
high premorbid %EBW lowered the odds of resumption
of menses. Using absolute BMI or BMI-SDS instead of
%EBW (for all time points) yielded almost identical results.
Discussion
In the present study, we investigated the resumption of
menses 12 months after the initiation of hospital treatmentin a large sample of female patients with first-onset AN.
In 47% of the adolescent patients, menses spontaneously
returned within the first 12 months after admission.
This finding corresponds to the findings of previous
studies [18,29,30,33]. As expected, deviation from “normal
age-appropriate” BMI (%EBW) at the 12-month follow-up
had the largest impact on menstrual status. Patients who
resumed menses had an average BMI of almost 19 kg/m2
(or BMI-SDS: -0.8), whereas those who had not resumed
menstruation had, on average, a significantly lower BMI of
17.5 kg/m2 (BMI-SDS: -1.4). This result is in accordance
with previous studies in adolescent and adult AN patients.
Swenne et al. [28] found that adolescent patients had a
BMI of 19.2 kg/m2 (or BMI-SDS: -0.59) when they started
menstruating again. In several studies in adult AN pa-
tients, the mean current BMI in those who had resumed
Figure 1 ROC of two different logistic regression models (red: model including premorbid %EBW, no menarche at admission, duration
of hospital treatment and regular discharge with target weight; black: model including premorbid %EBW, no menarche at admission,
duration of hospital treatment, regular discharge with target weight and %EBW at 12-month follow-up).
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and was significantly higher than the BMIs of patients
with persistent amenorrhea [24-26,29]. In the study of
Golden et al. [30], patients had a mean BMI percentile
of 27 at resumption of menses. Although the BMI at the
exact time point of resumption of menses was not evalu-
ated in our study, we found that those patients who were
menstruating at the 12-month follow-up had a similar
mean BMI percentile of 24. A recent study examined re-
sumption of menses in relation to %EBW and found that
two-thirds of the adolescent patients resumed menses at
weights of approximately 95% EBW [33]. Golden et al.
[27] also reported that 86% of the patients who achieved
approximately 90% of their standard body weight resumed
menses within 6 months. In our study, patients resumed
menstruation at a very similar %EBW. The mean %EBW
of the patients who spontaneously resumed menses was
91 at the 12-month follow-up, while those who were still
amenorrheic had weights of approximately 86% EBW.
However, in the present study and other studies, the
current (age-adjusted) BMIs of amenorrheic and menstruat-
ing girls exhibited considerable overlap [22,25,28,30,41,42],which suggests an impact of additional factors on the
resumption of menses.
Thus, an important aim of this study was the identifi-
cation of further anthropometric and clinical factors
that may predict the normalization of menstrual status
and are easily acquired at the time of initial hospital
treatment.
The absence of menarche at hospital admission strongly
predicted persistent amenorrhea at the 12-month follow-
up. Patients who did not have their menarche before the
onset of AN were unlikely to start menstruating within
the first 12 months after admission. This important find-
ing has not been reported previously. However, many
other studies included only patients with secondary amen-
orrhea (e.g., [22,25,29,41], while in our study, one-fifth of
the patients were still premenarchal at admission. The
finding that the absence of menarche before the onset
of AN predicted a worse outcome corresponds to the
results of other studies that a very low age at onset, e.g.,
childhood AN, is associated with a worse long-term out-
come compared with that in patients with adolescent
onset of AN [2,43,44].
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value. Patients who required longer hospital stays to reach
their target weights (16.8 weeks vs. 14.7 weeks) were more
likely to have persistent amenorrhea at the 12-month
follow-up. However, the factors underlying this finding
remain unclear. Longer hospital treatment durations
may imply more severe courses of illness that cause dif-
ficulties in gaining weight or considerable differences
between the weight at admission and the target weight.
In our study, the different variables at discharge, such as
%EBW, regular discharge at target weight, and duration
of treatment, were strongly related, and their individual
effects could not be precisely distinguished. Willer et al.
[45] also reported that increased lengths of hospital stays
predicted rehospitalization, which may be an indicator
of worse outcomes. However, longer hospital treatment
durations also shortened the time between discharge
(discharge normally occurred when the target weight was
maintained for two weeks) and the 12-month follow-up. It
has previously been shown that the length of time after
weight rehabilitation is an important determinant of the
recovery of the menstrual cycle [22] and that some adoles-
cent girls with AN only resume menses several years after
weight restoration [21,27]. Thus, for complete recovery of
menstrual function, longer periods of weight stabilization
without energy deficits may be necessary [23].
The achievement of target weight (defined as the
15-20th age-adjusted BMI percentile) before discharge
from hospital treatment was a significant positive pre-
dictor of the resumption of menses at the 12-month
follow-up. After adjusting for other relevant clinical vari-
ables, patients with high premorbid BMIs were found to
be less likely to resume menses by the follow-up, most
likely because there was still a significant difference
between target weight (as defined above) and the weight
at which menstruation was suspended. Accordingly, the
findings of other studies indicated that premorbid weight
[25,26] and the weight at which menstruation ceased may
help to predict the weight required for the return of men-
struation [27,28]. Thus, the determination of an adequate
target weight is essential, as sufficient weight rehabilitation
and stabilization are necessary for the resumption of
menses. Especially in young patients with AN, weight
restoration and recovery of hypothalamic-pituitary-gonadal
function are of particular importance, as they are the most
important preconditions for bone recovery [13,46]. In
addition, sex hormones were shown to be of great import-
ance for brain maturation during adolescence [17,47].
Growth charts based on large population-based data
sets can aid in the estimation of appropriate ranges of
expected weights based on current age and height. In
adolescents with secondary amenorrhea, the weight at
which menstruation ceased and premorbid weight should
also be considered. Based on our findings and those ofothers, a target weight between the 15th and 20th BMI per-
centile seems to be an adequate treatment goal.
Strengths and limitations
Some limitations of the present study should be consid-
ered. First, the time of follow-up was limited to 12 months.
Second, the study only included young, non-chronic
patients with a relatively short duration of illness and
moderate to severe AN. Thus, our results may not be
applicable to patients with more chronic courses of AN.
Third, biological parameters, such as hormone levels (e.g.,
gonadotropins, estrogens, and leptin), or data on body
composition that may also influence the resumption of
menses have not been investigated.
The study also has several methodological advantages.
We investigated a large sample of adolescent AN patients
who participated in a standardized treatment program
and had a low rate of loss to follow-up. The patients in
our sample represented a typical population of adolescents
with AN seeking inpatient treatment [48-51]. In addition,
we were able to assess a rather young sample consisting of
a large number of premenarchal patients, which allowed us
to demonstrate that early AN onset may result in protracted
hormonal deficits. Finally, follow-up data were assessed per-
sonally by well-trained and experienced therapists.
Conclusions
The recovery of menstrual function in adolescent patients
with AN should be a major treatment goal to prevent se-
vere long-term somatic and psychiatric sequelae. Patients
with premenarchal onset of AN and those with a high pre-
morbid BMI are obviously at particular risk for protracted
amenorrhea despite weight rehabilitation. While these two
risk factors cannot be influenced by treatment, others can
be addressed by adequate treatment strategies. In particu-
lar, discharging patients only after they have reached their
individual target weight and supporting them to maintain
this weight can influence outcome positively. The calcu-
lation of an individual target weight should be based on
population-based reference data. A target weight corre-
sponding to a range between the 15th and 20th BMI per-
centile seems to be favorable in terms of the resumption of
menses. Whether patients with a higher premorbid BMI
may benefit from a higher target weight should be in-
vestigated in further studies.
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